Article
California Legislation Increases Antitrust Scrutiny Of Patent Settlements Between Branded And Generic Pharmaceutical Manufacturers
On October 7, 2019, California enacted Assembly Bill 824 (AB 824)[1] in an effort to increase antitrust scrutiny of patent settlement agreements between branded and generic pharmaceutical manufacturer
Gibson, Dunn & Crutcher

